[Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].
K
K
Akiya
Y
Y
Negishi
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007375:Interleukin-1 / Q000627:therapeutic use; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D010844:Picibanil / Q000627:therapeutic use; D013935:Thymic Factor, Circulating / Q000627:therapeutic use; D013947:Thymosin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D007375:Interleukin-1; D007978:Levamisole; D010844:Picibanil; D013947:Thymosin; D007372:Interferons; D013935:Thymic Factor, Circulating; D007930:Leucine; C012211:ubenimex